MUMBAI, India, Feb. 6 -- Intellectual Property India has published a patent application (202511133171 A) filed by Isf College Of Pharmacy, Moga, Punjab, on Dec. 29, 2025, for 'development and characterization of folic acid conjugated chitosan nanoparticles of noscapine and resveratrol for the management of colon cancer.'
Inventor(s) include Nandini Sharma; Yukta Garg; Dr. Amandeep Singh; Sachin Yadav; Daksh Thakur; Dr. Manish Kumar; Dr. R. K. Narang; and Dr. Rajveer Singh.
The application for the patent was published on Feb. 6, under issue no. 06/2026.
According to the abstract released by the Intellectual Property India: "The procedure entails the development of folic acid-conjugated chitosan nanoparticles co-loaded with noscapine and resveratrol, designed for targeted delivery to the colon. The nanoparticles are prepared using the ionic gelation method, followed by surface conjugation with folic acid. The resulting formulation exhibits high stability, enhanced entrapment efficiency, controlled release, and improved bioavailability of the encapsulated drugs. Furthermore, folic acid conjugation enables receptor-mediated uptake by colon cancer cells, thereby ensuring site-specific targeting and minimizing systemic toxicity. The invention combines the synergistic anticancer effects of noscapine and resveratrol with the benefits of nanotechnology-based drug delivery, resulting in a promising therapeutic approach for colon cancer. The characterization methods of the invention include particle size analysis, PDI, entrapment efficiency, FTIR, DSC, SEM and in-vitro drug release thereby ensuring quality, efficacy, and safety of the nanoparticles. This innovative nanocarrier system has the potential to significantly improve the treatment of colon cancer by enhancing therapeutic efficacy, reducing adverse effects, and improving patient compliance, ultimately leading to better clinical outcomes and quality of life."
Disclaimer: Curated by HT Syndication.
